Ibogaine
Ibogaine (iboga; Tabernanthe iboga; noribogaine)
Evidence grade varies by use. See the breakdown on the entry. Read how the Atlas grades evidence.
Human evidence is limited and almost entirely observational. There are no completed adequately powered randomized controlled trials for any indication as of 2026. The strongest human signal for opioid use disorder comes from open-label observational cohorts and clinic case series reporting that a single dose can sharply reduce acute withdrawal symptoms and short-term craving; these lack control groups and blinding. For trauma indications, the authors of an uncontrolled open-label study of 30 Special Operations veterans (Stanford MISTIC protocol, magnesium co-administered, published in Nature Medicine in 2024) reported large reductions in PTSD, depression, and anxiety scores, but those same authors cautioned that travel, group setting, expectancy, and other nonspecific factors could not be separated out. Set against this are documented fatalities and consistent QTc prolongation. The honest grade is grade 2: a real and repeatedly observed clinical signal, not yet tested in controlled trials.
Reference only. Not medical advice.
| Treatment | Grade | Notes |
|---|---|---|
| Opioid withdrawal interruption (acute) | 2 of 5 | Repeated observational and open-label clinic reports of rapid, large reductions in acute withdrawal symptoms after a single dose; no completed controlled trials. A real but uncontrolled signal. |
| Opioid use disorder (sustained abstinence) | 2 of 5 | Case series suggest some people reach abstinence, but follow-up is short, dropout and relapse are under-reported, and there is no controlled long-term outcome data. |
| PTSD / traumatic brain injury sequelae (veterans) | 2 of 5 | One open-label uncontrolled study of 30 veterans (Stanford MISTIC, 2024) reported large improvements; the authors stress expectancy and setting were not controlled. Promising, unproven. |
| Stimulant (cocaine) use disorder | 1 of 5 | Limited observational reports and small underpowered studies; signal is weaker and less consistent than for opioids. |
| Depression / mood (standalone) | 1 of 5 | Mood improvements are reported alongside other indications but not isolated in controlled designs; theory and anecdote outpace direct evidence. |
What can go wrong
Serious. Ibogaine prolongs the QTc interval and has caused fatal ventricular arrhythmias, including torsades de pointes, sometimes in people without known heart disease and at therapeutic doses. Reviews tallied roughly 19 deaths temporally linked to ibogaine between 1990 and 2008, most in unsupervised or under-monitored settings, with several attributed to cardiac arrest. Bradycardia, severe ataxia, seizures, and prolonged effects requiring days of supportive care are also reported. Risk concentrates in uncontrolled clinic and retreat environments without pre-screening or continuous cardiac monitoring. Co-administered magnesium and electrolyte management are used in research protocols to reduce, not eliminate, cardiac risk.
This is something to take to a clinician. The Atlas can tell you what is known about ibogaine in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Ibogaine is a psychoactive alkaloid extracted from the root bark of iboga (Tabernanthe iboga), the central sacrament of the Bwiti religion of Gabon. Outside that ceremonial home it is studied for a striking and repeatedly reported effect: clinics and researchers report that a single supervised dose appears, in observational settings, to interrupt acute opioid withdrawal and blunt craving, and uncontrolled work in veterans points to reported improvements in PTSD, depression, and trauma after brain injury. The catch is twofold. The human evidence base remains observational, with no completed controlled trials, so the size and durability of any benefit are unproven. And ibogaine carries a documented, sometimes fatal, cardiac liability through QTc prolongation, with deaths recorded in unmonitored settings. Momentum is now considerable: Texas committed roughly $50 million to clinical trials in 2025, and a 2026 federal executive order named ibogaine among psychedelics targeted for accelerated review, driven heavily by veteran advocacy. Mexico and New Zealand permit clinical use under physician oversight while it stays Schedule I in the United States.
A sacred Central African initiation medicine that Western clinics reframed as a single-dose addiction interrupter, carrying both striking anecdotes and a documented record of cardiac deaths.
How it is supposed to work
Established pharmacology: ibogaine is metabolized by the liver enzyme CYP2D6 into a long-lived metabolite, noribogaine, that persists for one to several days. Both are described as binding many central nervous system targets, including NMDA, kappa- and mu-opioid, nicotinic acetylcholine, and 5-HT2A/5-HT3 receptors, plus the serotonin and dopamine transporters. Ibogaine and noribogaine also block the hERG cardiac potassium channel, the documented basis of QTc prolongation. Proposed (not established) mechanism for the anti-addiction effect: proponents and preclinical work describe upregulation of glial cell line-derived neurotrophic factor (GDNF) in dopaminergic circuits and a broader neuroplasticity-promoting ("psychoplastogen") action thought to reset reward and withdrawal pathways. The link between any single receptor action and the reported interruption of opioid withdrawal in humans remains inferred rather than demonstrated.
What people get wrong
Often saidIbogaine is a proven cure for addiction backed by clinical trials.
ActuallyAs of 2026 there are no completed adequately powered randomized controlled trials; the human evidence is observational and open-label, graded grade 2.
Often saidIt is a plant medicine, so it is gentle and safe.
ActuallyIbogaine blocks a cardiac potassium channel and has caused fatal arrhythmias, including in people without known heart disease; continuous cardiac monitoring is considered essential.
Who profits, and who pushes back
Nolan Williams, Stanford psychiatrist (MISTIC study lead)
The veterans in our open-label study showed large, sustained reductions in PTSD, depression, and anxiety, which is why we are calling for randomized controlled replication rather than treating this as settled.
Americans for Ibogaine (veteran advocacy group)
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
For veterans with treatment-resistant PTSD and traumatic brain injury, ibogaine has been life-changing, and federal action to accelerate research is long overdue.
Authors of the 2026 Addiction review on ibogaine and cardiovascular complications
Ibogaine carries a rare but clinically relevant risk of prolonged QT interval and ventricular arrhythmia, and that risk has to be weighed against an efficacy case that remains uncontrolled.
Bwiti community representatives and Gabonese heritage advocates
Iboga is our sacrament and our national heritage; foreign demand for the root must not come at the cost of the plant or the people who keep the practice.
Where the research comes from
Most of the published research on this comes from one place. 95% of it is from Central Africa (Gabon / Bwiti homeland). Findings that no unrelated group has reproduced are weaker than the study count makes them look.
| Place | Share of published research |
|---|---|
| Central Africa (Gabon / Bwiti homeland) | 95% |
| Mexico (treatment clinics) | 85% |
| United States (advocacy, new trials) | 80% |
| New Zealand (prescribed clinical use) | 55% |
| Western Europe | 40% |
How we got here
Iboga (Tabernanthe iboga) is rooted first in the equatorial forests of Central Africa, where the Babongo (Bongo) forest peoples of present-day Gabon are credited with its earliest ceremonial use. Knowledge of the root bark passed to neighboring Bantu groups, and by the 19th century it anchored the Bwiti religion practiced by the Fang and Mitsogo peoples of Gabon and parts of Cameroon and the Republic of Congo. In Bwiti, the powdered root bark is eaten in multi-day initiation rites that mark passage into adulthood and the community, taken in doses meant to bring the initiate face to face with ancestors. French colonial actors documented these rites in the late 1800s, and French pharmacologists isolated the principal alkaloid, naming it ibogaine, in 1901. The compound that Western clinics now study for opioid withdrawal is therefore an extract of a living African sacrament, not a laboratory invention.
Iboga's documented story begins with the Babongo forest peoples of Central Africa and spread through Bantu communities into the Bwiti religion of the Fang and Mitsogo of Gabon, where it has structured initiation rites for generations. French colonial observers recorded Bwiti ceremonies in the late 19th century, and ibogaine was isolated and named by French pharmacology in 1901. A pivotal turn came outside both Africa and formal medicine: in 1962, Howard Lotsof, a young American then dependent on heroin, reported that an iboga dose abolished his withdrawal, and he spent decades championing ibogaine as an addiction interrupter. As the United States placed ibogaine in Schedule I in 1970, a clinical underground formed in Mexico, the Caribbean, and later New Zealand. The 2020s brought the practice toward the mainstream through veteran-led advocacy, the 2024 Stanford veterans study, Texas state funding in 2025, and a 2026 federal executive order.
- Pre-1800sIboga used in Bwiti initiation rites in Gabon; earliest ceremonial use credited to the Babongo forest peoples.
- 1901French pharmacologists isolate the principal alkaloid and name it ibogaine.
- 1962Howard Lotsof reports that iboga abolished his heroin withdrawal, launching decades of addiction-interruption advocacy.
- 2024Open-label Stanford study of 30 veterans (magnesium-ibogaine, MISTIC) published in Nature Medicine reports large PTSD, depression, and anxiety improvements.
- 2025-2026Texas SB 2308 commits roughly $50M to trials (UTMB/UTHealth awarded Dec 2025); April 2026 federal executive order names ibogaine for accelerated FDA review.
How it is understood
Iboga remains the central sacrament of Bwiti, an active religion in Gabon where it has been recognized as part of the national cultural heritage. Wild Tabernanthe iboga is slow-growing and increasingly pressured by foreign demand, raising sovereignty and benefit-sharing concerns for the communities who hold the tradition.
Where scholars disagree
Iboga is the living sacrament of the Bwiti religion and is recognized as part of Gabonese national cultural heritage. Rising foreign demand for treatment-grade root bark pressures a slow-growing wild plant and the communities who steward it, raising unresolved questions about consent, benefit-sharing, and over-harvesting. Synthetic and semi-synthetic ibogaine and noribogaine routes are partly framed as ways to relieve that pressure, but commercialization of the knowledge and the plant proceeds largely without Gabonese governance.
Whether the repeatedly observed interruption of opioid withdrawal is a genuine, reproducible drug effect worth scaling, or an anecdote-rich finding that uncontrolled settings, expectancy, and selection have inflated, remains contested. The clinical observation and the proposed neuroplasticity mechanism are treated as separate claims with separate, low, evidence.
Ibogaine clinicians, veteran advocacy groups (for example Americans for Ibogaine), and several academic researchers
A single supervised dose reliably interrupts acute opioid withdrawal and craving and can produce durable trauma and mood benefit, a consistency across decades and settings that they argue justifies rapid, well-funded clinical translation under cardiac monitoring.
What it rests onDecades of convergent open-label and observational clinic data plus the 2024 Stanford open-label veterans study reporting large, sustained psychiatric improvement.
Addiction-medicine and cardiology reviewers writing in journals such as Addiction
The human evidence is too uncontrolled to establish efficacy, the benefit may be substantially nonspecific, and a documented, sometimes fatal, cardiac liability means enthusiasm has run ahead of proof.
What it rests onAbsence of any completed randomized controlled trial, under-reported relapse and dropout in case series, and a literature of QTc prolongation, torsades de pointes, and deaths in uncontrolled settings.
This disagreement is live. It has not settled.
At a glance
- Plant and source
- Root bark of iboga (Tabernanthe iboga), a Central African shrub; alkaloid isolated and named in 1901.
- Sacred origin
- Central sacrament of the Bwiti religion of Gabon (Fang, Mitsogo peoples; earliest use credited to Babongo forest peoples).
- Active metabolite
- Converted by liver CYP2D6 into long-lived noribogaine, which persists for one to several days.
- Key safety issue
- QTc prolongation and torsades de pointes; roughly 19 deaths temporally linked to ibogaine were reported between 1990 and 2008, mostly in unmonitored settings.
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Ibogaine. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- What people take it for. We have not catalogued the claims made for it.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.